Koru Medical Systems, INC

KORU Medical Systems, Inc. has amended its manufacturing and supply agreement with Command Medical Products, LLC, extending the term, modifying pricing, and establishing a second manufacturing site.

KORU Medical Systems, Inc. reported voting results from its 2026 Annual Meeting of Shareholders, with all director nominees elected and key proposals approved.

KORU Medical Systems reported a 22% increase in first-quarter net revenues to $11.8 million, driven by core business growth and international expansion, while also reiterating full-year 2026 financial guidance.

KORU Medical Systems, Inc. has amended its loan and security agreement with HSBC Ventures USA Inc., extending credit facility maturities and adjusting covenants.

KORU Medical Systems announces CEO Linda Tharby's retirement and the appointment of Adam Kalbermatten as her successor, effective July 1, 2026, with a structured transition plan.

KORU Medical Systems announced robust fourth quarter and full year 2025 financial results, achieving significant revenue growth and positive adjusted EBITDA, while initiating optimistic 2026 guidance.

Koru Medical Systems Inc. announced a 22.1% increase in net revenues for Q1 2026, driven by strong performance in its core domestic and international businesses, alongside significant growth in its pharma services segment.

KORU Medical Systems reported a significant reduction in net loss for Q3 2025, driven by robust international core revenue growth despite domestic declines.

KORU Medical Systems announced a significant increase in net revenues and a substantial reduction in net loss for the second quarter and first half of 2025, driven by core business expansion and pharma services.

KORU Medical Systems reports a 17.5% increase in net revenues for the first quarter of 2025, driven by growth in domestic and international core businesses.

Koru Medical Systems saw a 16.8% increase in revenue in the third quarter of 2024, driven by growth in both its core business and novel therapies segment.

KORU Medical Systems saw a significant 21.5% increase in revenue in the second quarter of 2024, driven by growth in both core and novel therapies businesses.

KORU Medical Systems reports an 18% increase in net revenues for the year ended December 31, 2024, driven by growth in core domestic and international businesses and novel therapies.

Koru Medical Systems experienced a slight revenue increase in 2023, driven by core business growth, but faced a larger net loss due to a deferred tax asset valuation allowance.

Adam R Kalbermatten, President and CEO of KORU Medical Systems, Inc., received 284,091 shares of common stock on July 1, 2026.

Koru Medical Systems, Inc. reports that President and CEO Adam R. Kalbermatten was granted performance stock units under his employment agreement.

Koru Medical Systems Director Edward Whihhan reports acquisition of 3,571 shares of common stock.

Matin Shahriar, a Director at KORU Medical Systems, Inc., reported the acquisition of 3,571 shares of common stock on July 1, 2026.

Donna French, a Director at KORU Medical Systems, Inc., reported the acquisition of 3,571 shares of common stock on July 1, 2026.

KORU Medical Systems Director John R. Fletcher acquired 5,357 shares of common stock on July 1, 2026, at a price of $4.20 per share.

KORU Medical Systems, Inc. has issued its definitive proxy statement detailing the agenda for its 2026 Annual Meeting of Shareholders, including the election of directors and an amendment to its equity incentive plan.

KORU Medical Systems announces its 2025 Annual Meeting of Shareholders to be held on May 14, 2025, covering director elections, executive compensation, and auditor ratification.

KORU Medical Systems will hold its 2024 Annual Meeting of Shareholders on May 9, 2024, to vote on director elections, executive compensation, auditor ratification, and an equity incentive plan.

Horton Capital Partners and Joseph M. Manko, Jr. filed an amended Schedule 13D detailing changes in their beneficial ownership of KORU Medical Systems, Inc. common stock, including share distributions and director compensation.

Horton Capital Partners and Joseph M. Manko, Jr. have filed an Amendment No. 11 to their Schedule 13D, detailing changes in their beneficial ownership of KORU Medical Systems, Inc. common stock, including share distributions to partners and director compensation.

BlackRock, Inc. has reported beneficial ownership of 5.6% of Koru Medical Systems Inc.'s common stock as of June 30, 2026.

Topline Capital Management, LP, and Collin McBirney have disclosed an 8.5% beneficial ownership stake in KORU Medical Systems, Inc., totaling 3,941,014 shares.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in KORU Medical Systems Inc., holding 2,345,369 shares of common stock.

First Light Asset Management, LLC and its managing member, Mathew P. Arens, have disclosed beneficial ownership of 10.23% and 10.46% respectively, of KORU Medical Systems, Inc.'s common stock, held for passive investment purposes.

First Light Asset Management, LLC and Mathew P. Arens have jointly disclosed their passive beneficial ownership of 9.74% and 9.98% respectively, of KORU Medical Systems, Inc.'s common stock as of December 31, 2024.